Evidence map›Paper›PMID 24167600›Full record

Trial reportPloS one2013

Collecting duct carcinomas represent a unique tumor entity based on genetic alterations.

Frank Becker, Kerstin Junker, Martin Parr, Arndt Hartmann, Susanne Füssel, Marieta Toma, Rainer Grobholz, Thomas Pflugmann, Bernd Wullich, Arne Strauss and 4 more

Registry-linked trialOpen access · goldAbstract readClinical TrialMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in PloS one, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05372302 (Collecting Ducts Carcinoma), which is not on this map. Cited by 18 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 2 pooled it
4.6field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05372302 unknown statusnot on this mapstarted 2021, after this paper: background citation

Collecting Ducts Carcinoma: in Depth Exploration and Biologically Driven Therapy (CICERONE)

TypeobservationalSponsorFondazione IRCCS Istituto Nazionale dei Tumori, MilanoRan2021 to 2022Enrolled100ConditionsCollecting Duct Carcinoma
3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 2 syntheses or guidelines pooled it, 38 citations in OpenAlex.

  1. New developments in existing WHO entities and evolving molecular concepts: The Genitourinary Pathology Society (GUPS) update on renal neoplasia.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2021
    Guideline
  2. SEOM clinical guidelines for the treatment of renal cell carcinoma.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2014
    Guideline
  3. Review
  4. Article
  5. Genomic alterations and diagnosis of renal cancer.Virchows Archiv : an international journal of pathology · 2024
    Review
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 7 institutions in 2 countries.

Frank BeckerDepartment of Urology, University of the Saarland, Homburg/Saar, Germany ; Urological Group Practice & Clinic Derouet/Pönicke/Becker, Boxberg Center, Neunkirchen, Germany ; for the German Network of Renal Cell Tumors, Jena, Germany.
Kerstin Junker
Martin Parr
Arndt Hartmann
Susanne Füssel
Marieta Toma
Rainer Grobholz
Thomas Pflugmann
Bernd Wullich
Arne Strauss
Carl Ludwig Behnes
Wolfgang Otto
Michael Stöckle
Volker Jung
Saarland University · DETU Dresden · DEUniversitätsklinikum Erlangen · DEUniversity of Göttingen · DECaritas-Krankenhaus St. Josef · DEKantonsspital Aarau · CHSt. Franziskus Hospital · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Collecting duct carcinoma (CDC) is a rare renal neoplasm that is associated with poor prognosis due to its highly aggressive course and limited response to immuno- or chemotherapy. Histologically, CDC is defined as a subtype of renal cell carcinomas, but in some cases, it is difficult to differentiate from urothelial carcinomas (UC). Therefore the aim of this study was to determine genetic alterations of CDC in comparison to that of urothelial carcinomas of the upper urinary tract (UUT-UC) to clarify the histological origin of this rare tumor entity. Twenty-nine CDC samples were obtained from seven different German centers and compared with twenty-six urothelial carcinomas of the upper urinary tract. Comparative genomic hybridization (CGH) was used to investigate the genetic composition of patients' tumors and allowed the detection of losses and gains of DNA copy numbers throughout the entire genome. The clinical data were correlated with CGH results. CGH analysis of CDC revealed DNA aberrations in many chromosomes. DNA losses were more frequently observed than gains, while high-level amplifications were not detected. The mean frequency of CDC chromosomal aberrations (4.9/case) was slightly lower than that in UUT-UC (5.4/case). Recurrent CDC DNA losses occurred at 8p (n=9/29), 16p (9/29), 1p (n=7/29) and 9p (n=7/29), and gains occurred in 13q (n=9/29). In contrast to CDC, the most frequently detected UUT-UC DNA aberration was a loss at 9q (n=13/26). DNA losses at 9q, 13q and 8q as well as gains at 8p showed significant variations in UUT-UC compared to CDC. There was no correlation between the patients' clinical course and the presence or absence of these recurrent genetic alterations. CDCs are characterized by a different genetic pattern compared to UUT-UC. Regarding the published data on renal cell carcinoma, we conclude that CDC appears to be a unique entity among kidney carcinomas.

Indexed as

Chromosome AberrationsAdultAgedAged, 80 and overCarcinoma, Renal CellChromosomes, HumanFemaleHumansKidney NeoplasmsMaleMiddle Aged

Identifiers

PMID24167600
PMCPMC3805592
OpenAlexW2058445901

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.